최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국해양바이오학회지 = Journal of marine bioscience and biotechnology, v.13 no.2, 2021년, pp.86 - 93
지선영 (동의대학교 항노화연구소) , 황보현 (동의대학교 항노화연구소) , 김민영 (동의대학교 항노화연구소) , 김다혜 (동의대학교 항노화연구소) , 박범수 (동의대학교 한의과대학 생화학교실) , 박정현 ((주)마린바이프로세스) , 이배진 ((주)마린바이프로세스) , 이혜숙 (동의대학교 항노화연구소) , 최영현 (동의대학교 한의과대학 생화학교실)
A high salt diet contributes to kidney damage by causing hypoxia and oxidative stress. Recently, an increase in dietary salt has been reported to induce an inflammatory phenotype in immune cells, further contributing to kidney damage. However, studies on the exact mechanism and role of a high salt d...
Bovee, D. M., Cuevas, C. A., Zietse, R., Danser, A. H. J., Mirabito Colafella, K. M., Hoorn, E. J. 2020. Salt-sensitive hypertension in chronic kidney disease: Distal tubular mechanisms. Am. J. Physiol. Renal Physiol. 319, F729-F745
Ren, J., Crowley, S. D. 2019. Role of T-cell activation in salt-sensitive hypertension. Am. J. Physiol. Heart Circ. Physiol. 316, H1345-H1353.
Mattson, D. L. 2014. Infiltrating immune cells in the kidney in salt-sensitive hypertension and renal injury. Am. J. Physiol. Renal Physiol. 307, F499-508.
Hirohama, D., Fujita, T. 2019. Evaluation of the pathophysiological mechanisms of salt-sensitive hypertension. Hypertens. Res. 42, 1848-1857.
Lu, X., Crowley, S. D. 2018. Inflammation in salt-sensitive hypertension and renal damage. Curr. Hypertens. Rep. 20, 103.
Saritas, T., Kramann, R. 2021. Kidney allograft fibrosis: Diagnostic and therapeutic strategies. Transplantation 105, e114-e130.
Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., Perkovic, V. 2021. Chronic kidney disease. Lancet 398, 786-802.
Molina, P., Gavela, E., Vizcaino, B., Huarte, E., Carrero, J. J. 2021. Optimizing diet to slow CKD progression. Front. Med. (Lausanne) 8, 654250.
Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., Kumar, S. 2021. Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. J. Exp. Pharmacol. 13, 303-328.
Brown, A., Kumar, S., Tchounwou, P. B. 2019. Cisplatin-based chemotherapy of human cancers. J. Cancer Sci. Ther. 11, 97.
Achkar, I. W., Abdulrahman, N., Al-Sulaiti, H., Joseph, J. M., Uddin, S., Mraiche, F. 2018. Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. J. Transl. Med. 16, 96.
Dasari, S., Tchounwou, P. B. 2014. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 740, 364-378.
McSweeney, K. R., Gadanec, L. K., Qaradakhi, T., Ali, B. A., Zulli A., Apostolopoulos, V. 2021, Mechanisms of cisplatin-induced acute kidney injury: Pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers (Basel) 13, 1572.
Xiang, X., Guo, C., Tang, C., Cai, J., Dong, Z. 2019. Epigenetic regulation in kidney toxicity: Insights from cisplatin nephrotoxicity. Semin. Nephrol. 39, 152-158.
Gentilin, E., Simoni, E., Candito, M., Cazzador, D., Astolfi, L. 2019. Cisplatin-induced ototoxicity: Updates on molecular targets. Trends Mol. Med. 25, 1123-1132.
Hajian, S., Rafieian-Kopaei, M., Nasri, H. 2014. Renoprotective effects of antioxidants against cisplatin nephrotoxicity. J. Nephropharmacol. 3, 39-42.
Holditch, S. J., Brown, C. N., Lombardi, A. M., Nguyen, K. N., Edelstein, C. L. 2019. Recent advances in models, mechanisms, biomarkers, and interventions in cisplatin-induced acute kidney injury. Int. J. Mol. Sci. 20, 3011.
Perse, M., Veceric-Haler, Z. 2018. Cisplatin-induced rodent model of kidney injury: Characteristics and challenges. Biomed. Res. Int. 2018, 1462802.
Taghizadeh, F., Hosseinimehr, S. J., Zargari, M., Karimpour Malekshah, A., Talebpour Amiri, F. B. 2020. Gliclazide attenuates cisplatin-induced nephrotoxicity through inhibiting NF-kappaB and caspase-3 activity. IUBMB Life 72, 2024-2033.
Abdelrahman, A. M., Al Suleimani, Y., Shalaby, A., Ashique, M., Manoj, P., Al-Saadi, H., Ali, B.H. 2019. Effect of levosimendan, a calcium sensitizer, on cisplatin-induced nephrotoxicity in rats. Toxicol. Rep. 6, 232-238.
Griffin, B. R., Faubel, S., Edelstein, C. L. 2019. Biomarkers of drug-induced kidney toxicity. Ther. Drug Monit. 41, 213-226.
Lin, S., Lin, W., Liao, C., Zhou, T. 2020. Nephroprotective effect of mesenchymal stem cell-based therapy of kidney disease induced by toxicants. Stem Cells Int. 2020, 8819757.
Wen, Y., Yan, H. R., Wang, B., Liu, B. C. 2021.,Macrophage heterogeneity in kidney injury and fibrosis. Front. Immunol. 12, 681748.
Sankhe, R., Kinra, M., Mudgal, J., Arora, D., Nampoothiri, M. 2020 Neprilysin, the kidney brush border neutral proteinase: a possible potential target for ischemic renal injury. Toxicol. Mech. Methods 30, 88-99.
Frazier, K. S., Ryan, A. M., Peterson, R. A., Obert, L. A. 2019. Kidney pathology and investigative nephrotoxicology strategies across species. Semin. Nephrol. 39, 190-201.
Dong, Q., Jie, Y., Ma, J., Li, C., Xin, T., Yang, D. 2019. Renal tubular cell death and inflammation response are regulated by the MAPK-ERK-CREB signaling pathway under hypoxia-reoxygenation injury. J Recept. Signal. Transduct. Res. 39, 383-391.
Belavgeni, A., Meyer, C., Stumpf, J., Hugo, C., Linkermann, A. 2020. Ferroptosis and necroptosis in the kidney. Cell. Chem. Biol. 27, 448-462.
Potocnjak, I., Domitrovic, R. 2016. Carvacrol attenuates acute kidney injury induced by cisplatin through suppression of ERK and PI3K/Akt activation. Food Chem. Toxicol. 98, 251-261.
Brooks, C. R., Bonventre, J. V. 2015. KIM-1/TIM-1 in proximal tubular cell immune response. Oncotarget 6, 44059-44060.
Karmakova, T. A., Sergeeva, N. S., Kanukoev, K. Y., Alekseev, B. Y., Kaprin, A. D. 2021. Kidney injury molecule 1 (KIM-1): a multifunctional glycoprotein and biological marker (Review). Sovrem. Tekhnologii. Med. 13, 64-78.
Soetikno, V., Sari, S. D. P., Ul Maknun, L., Sumbung, N. K., Rahmi, D. N. I., Pandhita, B. A. W., Louisa, M., Estuningtyas, A. 2019. Pre-treatment with curcumin ameliorates cisplatin-induced kidney damage by suppressing kidney inflammation and apoptosis in rats. Drug Res. (Stuttg) 69, 75-82.
Yang, R., Zhu, S., Tonnessen, T. I. 2016. Ethyl pyruvate is a novel anti-inflammatory agent to treat multiple inflammatory organ injuries. J. Inflamm. (Lond) 3, 13:37.
Zhao, Z., Hu, Z., Zeng, R., Yao, Y. 2020. HMGB1 in kidney diseases. Life Sci. 15, 259:118203.
Chen, Q., Guan, X., Zuo, X., Wang, J., Yin, W. 2016. The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases. Acta. Pharm. Sin. B. 6, 183-188.
Mehaffey, E., Majid, D. S. A. 2017. Tumor necrosis factor-alpha, kidney function, and hypertension. Am. J. Physiol. Renal Physiol. 313, F1005-F1008.
Basu, S. 2007. Novel cyclooxygenase-catalyzed bioactive prostaglandin F2 alpha from physiology to new principles in inflammation. Med. Res. Rev. 27, 435-468.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.